A new study from the American College of Cardiology has found that the popular ketogenic or "keto" diet may contribute to higher levels of "bad cholesterol" and a twofold increase in the risk of heart attacks and strokes.
“Our study found that regular consumption of a self-reported diet low in carbohydrates and high in fat was associated with increased levels of LDL cholesterol— or “bad” cholesterol—and a higher risk of heart disease,” said Dr. Iulia Iatan, MD, PhD, lead author of the study and attending physician-scientist at the Healthy Heart Program Prevention Clinic in St. Paul’s Hospital.
“To our knowledge, our study is one of the first to examine the association between this type of dietary pattern and cardiovascular outcomes.”
The study points out that depriving the body of carbohydrates such as bread, pasta, and rice forces the body to break down fat for energy instead. This breakdown produces ketones in the liver, hence the name keto. Advocates for this type of diet suggest obtaining 60 to 80 percent of calories from fat.
By comparing this low-carbohydrate, high-fat (LCHF) diet with a more standard diet, the study found that it elevated levels of LDL cholesterol in some people, which is known to elevate the risk of heart disease.
Before starting this dietary pattern, they should consult a healthcare provider," Iatan said. "While on the diet, it is recommended they have their cholesterol levels monitored and should try to address other risk factors for heart disease or stroke, such as diabetes, high blood pressure, physical inactivity and smoking.”
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
Join Cheddar News as we break down the top headlines this morning including updates on the Jan. 6 hears, the PGA suspension of 17 of the world's best golfers, and NASA's plans to study UFOs.
Rick Pauls, President & CEO OF DiaMedica Therapeutics, joins Cheddar Innovates to discuss a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients.
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
Catching you up on the stories you need to know this morning, mass shooting victims testify on Capitol Hill, the White House outlines its plan to vaccinate kids younger than five years old, and we break down how to protect yourself from monkeypox.
The pharmaceutical giant Moderna says its updated 'bivalent' booster shot provides a stronger immune response against the Omicron variant of COVID-19 specifically. This week, Moderna plans to submit preliminary data to U.S. health officials in the hopes that its new booster will be available later this summer. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
NASA has announced that the first official full-color images will be beamed back to Earth from the James Webb Telescope on July 12. Gregory L. Robinson, the director of the James Webb Space Telescope Program in the NASA Science Mission Directorate, joined Cheddar News to discuss the anticipated image drop. “We expect to see the universe different," he said. "Webb will allow us to see much, much clearer and deeper into the universe."
On this episode of Cheddar Reveals, Professor Laurence Hurst, Director of The Milner Centre for Evolution, discusses the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up? Neville Sanjana, faculty member at NY Genome and New York University, breaks down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases; Cheddar gets a look at Curiosity Stream's 'The Butterfly Effect.'
Neville Sanjana, faculty member at NY Genome and New York University, joins Cheddar Reveals to break down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases.
